Convalescent plasma anti SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
- 30 November 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 130 (12), 6728-6738
- https://doi.org/10.1172/JCI141206
Abstract
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied the relationship among anti-spike ectodomain (anti-ECD), anti-receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by 2 in vitro assays using convalescent plasma samples from 68 patients with COVID-19. We report a strong positive correlation between both plasma anti-RBD and anti-ECD IgG titers and in vitro VN titers. The probability of a VN titer of >= 160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment, was >= 80% when anti-RBD or anti-ECD titers were >= 1:1350. Of all donors, 37% lacked VN titers of >= 160. Dyspnea, hospitalization, and disease severity were significantly associated with higher VN titer. Frequent donation of convalescent plasma did not significantly decrease VN or IgG titers. Analysis of 2814 asymptomatic adults found 73 individuals with anti-ECD IgG titers of >= 1:50 and strong positive correlation with anti-RBD and VN titers. Fourteen of these individuals had VN titers of >= 1:160, and all of them had anti-RBD titers of >= 1:1350. We conclude that anti-RBD or anti-ECD IgG titers can serve as a surrogate for VN titers to identify suitable plasma donors. Plasma anti-RBD or anti-ECD titers of >= 1:1350 may provide critical information about protection against COVID-19 disease.Keywords
Funding Information
- NIH (AI146771-01,AI139369-01)
- NIAID (75N93019C00050)
- Army Research Office (W911NF-12-1-0390)
This publication has 40 references indexed in Scilit:
- Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United StatesTransfusion, 2020
- Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against EbolavirusesCell, 2017
- Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirusProceedings of the National Academy of Sciences of the United States of America, 2015
- Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologymAbs, 2010
- Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution PathwayPLoS Pathogens, 2008
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesProceedings of the National Academy of Sciences of the United States of America, 2007
- Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsPLoS Medicine, 2006
- Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing AntibodyPublished by Elsevier BV ,2006
- Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndromeJournal of Clinical Virology, 2005
- Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor associationProceedings of the National Academy of Sciences of the United States of America, 2004